title: Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
abstract: The effects of MPC-1304, a new calcium channel blocker, on blood pressure, serum lipoproteins, and carbohydrate metabolism were compared with those of atenolol in a group of patients with mild to moderate essential hypertension. Systolic and diastolic pressures were significantly decreased by both MPC-1304 and atenolol administration. Serum levels of apolipoproteins A-I and A-II were significantly increased after 8-12 weeks of MPC-1304 treatment, but were unchanged during a similar period of atenolol treatment. Neither drug induced any significant change in other lipoprotein parameters, fasting blood sugar, immunoreactive insulin, C-peptide or HbA1c. No serious side-effects or abnormal laboratory values were observed during the course of administration of either drug. These findings indicated that MPC-1304 is as efficacious as an antihypertensive drug and is without adverse effect on lipoprotein or carbohydrate metabolism.
authors.affiliation: Second Department of Internal Medicine, Fukuoka University School of Medicine, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: G
authors.initials: G
authors.lastname: Kajiyama
authors.forename: R
authors.initials: R
authors.lastname: Kusukawa
authors.forename: M
authors.initials: M
authors.lastname: Shichiri
authors.forename: T
authors.initials: T
authors.lastname: Sunaga
authors.forename: H
authors.initials: H
authors.lastname: Mashiba
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Nonaka
authors.forename: K
authors.initials: K
authors.lastname: Arakawa
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016633:Apolipoprotein A-II / Q000097:blood; D001053:Apolipoproteins / Q000097:blood; D001262:Atenolol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects*; D002096:C-Peptide / Q000097:blood; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D016633:Apolipoprotein A-II; D001053:Apolipoproteins; D001786:Blood Glucose; D002096:C-Peptide; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D006454:Hemoglobins; D007328:Insulin; D008074:Lipoproteins; C059427:aranidipine; D001262:Atenolol